Patents by Inventor Frank Sainsbury
Frank Sainsbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11390878Abstract: A method of increasing the yield, stability, or both of an acid sensitive protein in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding the acid sensitive protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby increasing the yield of the acid sensitive protein when compared to the yield of the acid sensitive protein produced in the plant or portion of the plant produced under the same conditions, and in the absence of the proton channel protein.Type: GrantFiled: January 26, 2015Date of Patent: July 19, 2022Assignees: MEDICAGO INC., UNIVERSITE LAVALInventors: Marc-Andre D'Aoust, Manon Couture, Louis-Philippe Vezina, Dominique Michaud, Philippe Varennes-Jutras, Frank Sainsbury
-
Publication number: 20210155947Abstract: The invention is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (“CPMV-HT”) based protein expression system.Type: ApplicationFiled: September 9, 2020Publication date: May 27, 2021Inventors: Frank Sainsbury, George Peter Lomonossoff
-
Patent number: 10947549Abstract: The invention is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (“CPMV-HT”) based protein expression system.Type: GrantFiled: August 31, 2020Date of Patent: March 16, 2021Assignee: PLANT BIOSCIENCE LIMITEDInventors: Frank Sainsbury, George Peter Lomonossoff
-
Patent number: 10907168Abstract: A method of increasing expression of an heterologous protein of interest in a plant or portion of the plant is provided. The method comprises treating the plant or portion of the plant with a jasmonate-pathway activator, and introducing a nucleotide sequence operably linked to a regulatory region derived from a DNA plant virus and encoding the heterologous protein of interest into the plant or portion of the plant. Alternatively, the plant or plant portion may comprise the nucleic acid and encoding the heterologous protein of interest, and the plant or portion of the plant is treated with the jasmonate pathway activator. The treated plant is incubated under conditions to permit expression of the nucleotide sequence encoding the heterologous protein of interest.Type: GrantFiled: June 30, 2016Date of Patent: February 2, 2021Assignees: MEDICAGO INC., UNIVERSITE LAVALInventors: Marc-Andre D'Aoust, Stephanie Robert, Marie-Claire Goulet, Dominique Michaud, Frank Sainsbury
-
Publication number: 20200392522Abstract: The invention is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (“CPMV-HT”) based protein expression system.Type: ApplicationFiled: August 31, 2020Publication date: December 17, 2020Inventors: Frank Sainsbury, George Peter Lomonossoff
-
Patent number: 10822613Abstract: The invention is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (“CPMV-HT”) based protein expression system.Type: GrantFiled: August 11, 2017Date of Patent: November 3, 2020Assignee: PLANT BIOSCIENCE LIMITEDInventors: Frank Sainsbury, George Peter Lomonossoff
-
Publication number: 20180195078Abstract: A method of increasing expression of an heterologous protein of interest in a plant or portion of the plant is provided. The method comprises treating the plant or portion of the plant with a jasmonate-pathway activator, and introducing a nucleotide sequence operably linked to a regulatory region derived from a DNA plant virus and encoding the heterologous protein of interest into the plant or portion of the plant. Alternatively, the plant or plant portion may comprise the nucleic acid and encoding the heterologous protein of interest, and the plant or portion of the plant is treated with the jasmonate pathway activator. The treated plant is incubated under conditions to permit expression of the nucleotide sequence encoding the heterologous protein of interest.Type: ApplicationFiled: June 30, 2016Publication date: July 12, 2018Inventors: Marc-Andre D'AOUST, Stephanie ROBERT, Marie-Claire GOULET, Dominique MICHAUD, Frank SAINSBURY
-
Publication number: 20180030462Abstract: The invention is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (“CPMV-HT”) based protein expression system.Type: ApplicationFiled: August 11, 2017Publication date: February 1, 2018Inventors: Frank Sainsbury, George Peter Lomonossoff
-
Publication number: 20140250549Abstract: The invention is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (“CPMV-HT”) based protein expression system.Type: ApplicationFiled: February 4, 2014Publication date: September 4, 2014Applicant: PLANT BIOSCIENCE LIMITEDInventors: Frank Sainsbury, George Peter Lomonossoff
-
Patent number: 8674084Abstract: The inventions is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (‘CPMV-HT’) based protein expression system.Type: GrantFiled: January 8, 2009Date of Patent: March 18, 2014Assignee: Plant Bioscience LimitedInventors: Frank Sainsbury, George Peter Lomonossoff
-
Publication number: 20120174263Abstract: The invention provides methods of producing “empty” RNA virus capsids (e.g. from Cowpea mosaic virus) by assembly of viral small (S) and large (L) coat proteins in such a way that encapsidation of native viral RNA is avoided. Aspects of the invention employ in planta expression of capsid components from DNA vectors encoding the S and L proteins or S-L polyproteins including them. Such capsids have utility for the encapsidation or presentation of foreign proteins or desired payloads.Type: ApplicationFiled: June 15, 2010Publication date: July 5, 2012Applicant: PLANT BIOSCIENCE LIMITEDInventors: Keith Saunders, George Peter Lomonossoff, Frank Sainsbury
-
Publication number: 20120015899Abstract: Aspects of the invention provide modified virus-like particles that are designed for therapeutic applications. In particular, aspects of the invention provide CCMV coat proteins that are modified to generate virus-like particles, including mosaic virus-like particles, that can package and/or deliver one or more diagnostic and/or therapeutic agents. The invention also provides methods for treating subjects with one or more modified virus-like particles.Type: ApplicationFiled: October 25, 2009Publication date: January 19, 2012Applicants: Plant Bioscience, Limited, Aura BiosciencesInventors: George Lomonossoff, David Evans, Elisabet de los Pinos, Frank Sainsbury
-
Publication number: 20100287670Abstract: The inventions is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (‘CPMV-HT’) based protein expression system.Type: ApplicationFiled: January 8, 2009Publication date: November 11, 2010Inventors: Frank Sainsbury, George Peter Lomonossoff